PL373531A1 - Przeciwciało selektywne względem receptora dla liganda indukującego apoptozę spokrewnionego z czynnikiem martwicy nowotworu i jego zastosowania - Google Patents

Przeciwciało selektywne względem receptora dla liganda indukującego apoptozę spokrewnionego z czynnikiem martwicy nowotworu i jego zastosowania

Info

Publication number
PL373531A1
PL373531A1 PL02373531A PL37353102A PL373531A1 PL 373531 A1 PL373531 A1 PL 373531A1 PL 02373531 A PL02373531 A PL 02373531A PL 37353102 A PL37353102 A PL 37353102A PL 373531 A1 PL373531 A1 PL 373531A1
Authority
PL
Poland
Prior art keywords
necrosis factor
tumor necrosis
ligand receptor
inducing ligand
related apoptosis
Prior art date
Application number
PL02373531A
Other languages
English (en)
Other versions
PL211755B1 (pl
Inventor
Tong Zhou
Robert P. Kimberly
William J. Koopman
Albert F. Lobuglio
Donald J. Buchsbaum
Original Assignee
Uab Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uab Research Foundation filed Critical Uab Research Foundation
Publication of PL373531A1 publication Critical patent/PL373531A1/pl
Publication of PL211755B1 publication Critical patent/PL211755B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44—Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)

Abstract

Przeciwciało według wynalazku wchodzi w reakcję z ludzkim DR5 lub z ludzkim DR4 wytwarzając agonistyczne lub antagonistyczne efekty regulacji ujemnej receptora obejmujące hamowanie proliferacji komórkowej i apoptozy. Ujawniono sekwencje kwasu nukleinowego i sekwencje aminokwasowe przeciwciał DR5 i DR4 oraz wektory i komórki zawierające i eksprymujące te sekwencje były wygenerowane. Opisano szczegółowo sposoby i zastosowania dla tych przeciwciał włączając leczenie związanych z apoptozą chorób i leczenia nieprawidłowego wzrostu komórkowego.
PL373531A 2001-11-01 2002-11-01 Oczyszczone przeciwciało wiążące wybiórczo receptor DR4 dla TRAIL, sposób wybiórczego indukowania apoptozy w komórkach docelowych, sposób hamowania prolifereacji komórek docelowych, kompozycja farmaceutyczna zawierająca przeciwciało, zastosowanie przeciwciała, wyizolowany kwas nukleinowy, wektor, hodowana komórka i oczyszczony polipeptyd PL211755B1 (pl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US34640201P 2001-11-01 2001-11-01

Publications (2)

Publication Number Publication Date
PL373531A1 true PL373531A1 (pl) 2005-09-05
PL211755B1 PL211755B1 (pl) 2012-06-29

Family

ID=23359208

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373531A PL211755B1 (pl) 2001-11-01 2002-11-01 Oczyszczone przeciwciało wiążące wybiórczo receptor DR4 dla TRAIL, sposób wybiórczego indukowania apoptozy w komórkach docelowych, sposób hamowania prolifereacji komórek docelowych, kompozycja farmaceutyczna zawierająca przeciwciało, zastosowanie przeciwciała, wyizolowany kwas nukleinowy, wektor, hodowana komórka i oczyszczony polipeptyd

Country Status (19)

Country Link
EP (2) EP1506011B1 (pl)
JP (1) JP4371814B2 (pl)
KR (1) KR101004098B1 (pl)
CN (1) CN100482276C (pl)
AU (1) AU2002350121B2 (pl)
BR (1) BRPI0213844B8 (pl)
CA (1) CA2465040C (pl)
CO (1) CO5580833A2 (pl)
ES (1) ES2357225T3 (pl)
HU (1) HUP0700077A3 (pl)
IL (3) IL161685A0 (pl)
MX (1) MXPA04004185A (pl)
NO (1) NO338458B1 (pl)
NZ (1) NZ532591A (pl)
PL (1) PL211755B1 (pl)
RO (1) RO123115B1 (pl)
RU (1) RU2313537C2 (pl)
WO (1) WO2003037913A2 (pl)
ZA (2) ZA200403116B (pl)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
TWI318983B (en) 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
US7361341B2 (en) 2001-05-25 2008-04-22 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to trail receptors
US7348003B2 (en) 2001-05-25 2008-03-25 Human Genome Sciences, Inc. Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors
JP4509570B2 (ja) 2001-07-03 2010-07-21 ジェネンテック， インコーポレイテッド ヒトｄｒ４抗体及びその使用法
US20040089839A1 (en) 2002-10-25 2004-05-13 Honeywell International, Inc. Fluorinated alkene refrigerant compositions
AU2008201431B2 (en) * 2002-11-27 2011-11-24 Irm, Llc Methods and compositions for inducing Apoptosis in cancer cells
RU2379056C2 (ru) 2002-11-27 2010-01-20 Айрм Ллс Способы и композиции для индукции апоптоза раковых клеток
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
KR20070010046A (ko) * 2004-04-06 2007-01-19 제넨테크, 인크. Ｄｒ5 항체 및 그의 용도
ES2365719T3 (es) 2004-08-06 2011-10-10 Genentech, Inc. Ensayos y procedimientos que utilizan biomarcadores.
CN101061238B (zh) 2004-08-06 2013-11-20 健泰科生物技术公司 使用生物标志的测定法和方法
CN100427505C (zh) * 2004-08-19 2008-10-22 中国医学科学院基础医学研究所 抗人肿瘤坏死因子相关凋亡诱导配体的受体dr5单克隆抗体（ad5-10）及其制法与用途
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
US8029783B2 (en) 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
BRPI0615997A8 (pt) 2005-08-16 2018-05-22 Genentech Inc método para prever a sensibilidade de uma amostra de célula ou tecido, método para induzir apoptose em uma amostra de célula ou tecido e método de tratamento de uma disfunção
AU2007230868B2 (en) * 2006-01-13 2012-02-02 Irm Llc Antibodies against thymic stromal lymphopoietin receptor for treating allergic diseases
CN101074261A (zh) * 2006-04-30 2007-11-21 北京同为时代生物技术有限公司 Trail受体1和/或trail受体2特异性抗体及其应用
BRPI0718413A2 (pt) 2006-10-23 2014-03-11 The Uab Research Foundation Métodos para prever a sensibilidade de uma célula concerosa a um primeiro agente anticâncer, para prever ou monitorar a eficácia de um agente anticâncer, e para determinar uma dose eficaz para um agente anticâncer, kit de detecção, e, sistema de ensaio multiplex
CN101820913A (zh) * 2007-08-09 2010-09-01 第一三共株式会社 在表达含死亡结构域的受体的细胞中诱导细胞凋亡的免疫脂质体
RU2405038C1 (ru) * 2009-07-29 2010-11-27 Учреждение Российской академии наук Институт биоорганической химии им. академиков М.М. Шемякина и Ю.А. Овчинникова РАН Способ получения мутантного белка trail человека
CA2780130A1 (en) * 2009-11-05 2011-05-12 The Uab Research Foundation Treating basal-like genotype cancers
US9120855B2 (en) 2010-02-10 2015-09-01 Novartis Ag Biologic compounds directed against death receptor 5
US8703712B2 (en) 2010-03-18 2014-04-22 The Uab Research Foundation Targeting cancer stem cells with DR5 agonists
BR112013010574A2 (pt) 2010-10-29 2016-08-09 Daiichi Sankyo Co Ltd anticorpo, fragmento funcional do anticorpo, composição farmacêutica, usos de um anticorpo ou um fragmento funcional do mesmo e de pelo menos um membro selecionado do grupo que consiste de paclitaxel, carvoplatina, cpt-11, vinblastina, e 5-fu, polinucleotídeo, vetor, célula hospedeira transformada, e, método de produzir o anticorpo
RS67757B1 (sr) * 2011-04-29 2026-03-31 Penn State Res Found Indukcija malim molekulom trail gena u normalnim i tumorskim ćelijama kao antikancerska terapija
CN103833853B (zh) * 2013-12-25 2019-05-17 河南大学 新型死亡受体激动性多价抗体及其在制备抗肿瘤药物中的应用
CN107250161A (zh) 2015-01-26 2017-10-13 宏观基因有限公司 包含dr5‑结合结构域的多价分子
BR112018070452A2 (pt) * 2016-04-05 2019-02-05 Baliopharm Ag um inibidor do receptor de hutnfr1, uma preparação farmacêutica compreendendo o referido inibidor, um método de produção do referido inibidor, uso do referido inibidor na fabricação de um produto para tratamento de um indivíduo humano, um ácido nucleico isolado que codifica o referido inibidor, vetor de expressão e células hospedeiras compreendendo o referido ácido nucleico
WO2018138297A1 (en) 2017-01-27 2018-08-02 Kymab Limited Anti-opg antibodies
US20220221455A1 (en) * 2019-04-18 2022-07-14 Glaxosmithkline Biologicals Sa Antigen binding proteins and assays

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE362982T1 (de) * 1997-01-28 2007-06-15 Human Genome Sciences Inc ßDEATH-DOMAINß-ENTHALTENDER REZEPTOR 4 (DR4), EIN MITGLIED DER TNF-REZEPTOR SUPERFAMILIE, WELCHER AN TRAIL (APO-2L) BINDET
TR199902068T2 (xx) * 1997-02-28 1999-12-21 Boehringer Ingelheim Pharmaceuticals, Inc. �ltihap h�crelerinin gen tedavisi ile kendi kendini d�zenleyen apoptozu.
AU734758B2 (en) 1997-04-01 2001-06-21 Sankyo Company Limited Anti-fas antibodies
PT1053256E (pt) * 1998-01-26 2011-09-28 Genentech Inc Anticorpos para o receptor de morte 4 (dr4) e utilizações destes
US6252050B1 (en) * 1998-06-12 2001-06-26 Genentech, Inc. Method for making monoclonal antibodies and cross-reactive antibodies obtainable by the method
AU4984300A (en) * 1999-05-06 2000-11-21 Vishva M Dixit Death domain containing receptor 4
WO2000073349A1 (en) * 1999-05-28 2000-12-07 Genentech, Inc. Dr4 antibodies and uses thereof
TWI318983B (en) * 2000-05-02 2010-01-01 Uab Research Foundation An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof

Also Published As

Publication number Publication date
KR101004098B1 (ko) 2011-01-13
WO2003037913A3 (en) 2004-11-18
NZ532591A (en) 2008-04-30
ZA200507050B (en) 2010-03-31
EP2287285A3 (en) 2012-05-02
PL211755B1 (pl) 2012-06-29
ES2357225T3 (es) 2011-04-20
RU2004116475A (ru) 2005-04-20
IL161685A0 (en) 2004-09-27
ZA200403116B (en) 2006-06-28
EP1506011A4 (en) 2006-07-12
CN1655814A (zh) 2005-08-17
KR20040070349A (ko) 2004-08-07
MXPA04004185A (es) 2005-05-16
JP2005509414A (ja) 2005-04-14
BRPI0213844B1 (pt) 2018-12-26
RO123115B1 (ro) 2010-11-30
IL161685A (en) 2011-03-31
EP2287285A2 (en) 2011-02-23
BR0213844A (pt) 2006-05-23
BRPI0213844B8 (pt) 2021-05-25
HUP0700077A3 (en) 2012-09-28
RU2313537C2 (ru) 2007-12-27
CO5580833A2 (es) 2005-11-30
NO20042269L (no) 2004-06-30
CN100482276C (zh) 2009-04-29
CA2465040A1 (en) 2003-05-08
EP1506011B1 (en) 2015-08-19
JP4371814B2 (ja) 2009-11-25
CA2465040C (en) 2013-12-10
EP1506011A2 (en) 2005-02-16
HUP0700077A2 (en) 2007-05-02
IL196082A (en) 2011-04-28
WO2003037913A2 (en) 2003-05-08
NO338458B1 (no) 2016-08-15
AU2002350121B2 (en) 2007-09-06

Similar Documents

Publication Publication Date Title
HUP0400951A2 (hu) Egy tumornekrózis faktorral rokon apoptózis indikáló ligandum receptorára specifikus antitest és alkalmazásai
WO2003037913A3 (en) An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof
NO20042266L (no) Kombinasjoner av antistoffer selektive for en tumor nekrose faktor-relatert apoptose-induserende ligandreseptor og andre terapeutiske midler
DK1408984T3 (da) Organofosforforbindelser til aktivering af gamma/delta T celler
WO2004063362A3 (en) Cell cycle progression proteins
ATE526019T1 (de) Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
CY1111371T1 (el) Αντισωματα bag3 για χρηση σε ερευνα, διαγνωση και θεραπεια ασθενειων που σχετιζονται με κυτταρικο θανατο
DE50106127D1 (de) Verwendung von trifunktionellen bispezifischen und trispezifischen antikörpern zur behandlung von malignem aszites
DK0784683T3 (da) TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
YU9404A (sh) Multimerna, usmerena kontrastna sredstva na bazi peptida
EA201300481A1 (ru) АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
DK0961780T3 (da) Proteinmarkörer for lungecancer og anvendelse deraf
IL163902A0 (en) Antibodies against cancer antigen tmeff2 and uses thereof
WO2006029219A3 (en) Human monoclonal anti-ctla4 antibodies in cancer treatment
ATE527378T1 (de) Antisense-modulation von p38-mitogen-aktivierter proteinkinase-expression
PT1087993E (pt) Péptidos fas e anticorpos para modular a apoptose
UA84954C2 (ru) Конденсированные пиримидоны, пригодные для лечения и профилактики злокачественного новообразования
TW200635946A (en) Binding proteins specific for human matriptase
ATE287722T1 (de) Mittel zur behandlung maligner erkrankungen unter verwendung des proteins yb-1
EA200500934A1 (ru) Соединения, модулирующие активность киназного белка множественных линий, и способы лечения нейродегенеративных и воспалительных заболеваний
God et al. Disruption of HLA class II antigen presentation in Burkitt lymphoma: implication of a 47 000 MW acid labile protein in CD4+ T‐cell recognition
DK1234025T3 (da) Humane enzymer fra metalloproteasefamilien
DE60229867D1 (de) Zielgerichtete ligande gegen peyer's flecke- und/oder m-zellen
CY1106289T1 (el) Χρηση αναστολεων υποδοχεος προγεστepονης για τη θepαπευτικη αντιμετωπιση του καρκινου του μαστου που ειναι ανθεκτικος σε στepοειδη